不同剂量紫杉醇联合卡铂治疗晚期卵巢癌的疗效比较  

Comparison of the Efficacy of Different Doses of Paclitaxel Combined With Carboplatin in the Treatment of Advanced Ovarian Cancer

作　　者：葛岩[1] 周莉[2] GE Yan ZHOU Li(Obstetrics and Gynecology Department, Jilin Maternal and Child Health Care Hospital, Changchun Jilin 130061, China The Second of Department of Gynecologic Oncology, Jilin Tumor Hospital, Changchun Jilin 130012, China)

机构地区：[1]吉林省妇幼保健院妇产科,吉林长春130061 [2]吉林省肿瘤医院妇瘤二科,吉林长春130012

出　　处：《中国卫生标准管理》2017年第9期67-68,共2页China Health Standard Management

摘　　要：目的分析不同剂量紫杉醇联合卡铂治疗晚期卵巢癌的临床疗效。方法将52例晚期卵巢癌患者随机分为两组,均给予300~400mg/m^2卡铂静滴3 h,另外对照组给予3h175 mg/m^2紫杉醇静滴,观察组给予24 h 135 mg/m^2紫杉醇静滴。结果两组治疗总有效率对比,差异无统计学意义(P>0.05),观察组不良反应发生率均低于对照组(P<0.05)。结论对晚期卵巢癌在卡铂治疗时给予3h 175 mg/m^2紫杉醇、24h 135mg/m^2紫杉醇静滴的疗效相当,但后者更为安全。Objective To evaluate the clinical effect of different doses of paclitaxel combined with carboplatin in the treatment of advanced ovarian cancer. Methods 52 cases of patients with advanced ovarian cancer were randomly divided into two groups, were given intravenous drip of 3 h platinum 300 - 400 mg/m2, the control group was given 3 h 175 mg/m2 paclitaxel infusion, the observation group was given intravenous paclitaxel 24 h 135 mg/m2. Results The total efficiency of two groups had no significant difference （P 〉 0.05）. The adverse reaction rate of observation group were significantly lower than the control group （P 〈 0.05）. Conclusion For advanced ovarian cancer given 3 h 175 mg/m2 paclitaxel in carboplatin, 24 h 135 mg/m2 paclitaxel infusion efficacy, but the latter is more for safety.

关 键 词：卵巢癌 晚期 卡铂 紫杉醇 给药剂量 

分 类 号：G642[文化科学—高等教育学]